Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com - Capricor Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Capricor Therapeutics announced earnings per share of $-0.260 on revenue of $1.59M. Analysts polled by Investing.com EPS of $-0.270 on revenue of $420K.
Capricor Therapeutics 's are down 53.92% and is trading at $4.900 , still down 25.53% from its 52 week high of $6.58 set on Thursday, October 13, 2022.
Capricor Therapeutics follows other major Healthcare sector earnings this month
Capricor Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar